drugset / Trial / NCT00207701

A Study of Infliximab (Remicade) in Patients With Ankylosing Spondylitis.

NCT00207701

Phase 3 Completed 279 enrolled Centocor, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

A study of the safety and efficacy of Infliximab (Remicade) versus placebo in subjects with Ankylosing Spondylitis

Timeline

Start
2002-09
Primary completion
Completion
2005-02

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Infliximab Monoclonal antibody 5 mg/kg